Investigational drug · Phase 2
BI-1607
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BI-1607"
First trial start
2024
Dec 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI-1607", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma Metastatic
- Melanoma of Skin
- Melanoma BRAF V600E/K Mutated
- Melanoma Recurrent
- Melanoma Stage III or IV
- Melanoma
- Melanoma Negative for bRAF
- Melanoma Negative for nRAS
- Melanomas
- Uveal Melanoma, Metastatic
Approved drugs for the same conditions: Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "BI-1607" as an intervention, largest first.
- Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaActive, not recruiting
BioInvent International ABIndustry
NCT06784648 · 35 participants (planned) · Start Dec 11, 2024 · Primary completion Sep 9, 2026
Drug: pembrolizumab (KEYTRUDA®); BI-1607 and 1 more · For: Melanoma Metastatic; Melanoma of Skin; Melanoma BRAF V600E/K Mutated and 7 more
Sites: Heidelberg, Germany; Barcelona, Spain; Madrid, Spain · 4 sites in all
- BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid TumorsTerminated
BioInvent International ABIndustry
NCT05555251 · 18 participants · Start Jul 28, 2022 · Primary completion Feb 7, 2024
Drug: BI-1607; BI-1607 and 1 more · For: HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Metastatic Breast Cancer and 2 more
Sites: Essen, Germany; Frankfurt, Germany; Barcelona, Spain · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.
Oldham RJ, Mårtensson L, Semmrich M, et al. · J Exp Clin Cancer Res 2026
- A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.
Cortés J, Priego A, Garralda E, et al. · Clin Cancer Res 2025
Also in development for Melanoma Metastatic
- BCD-217Phase 32 trials
Biocad · Melanoma Stage III, Melanoma (Skin), Melanoma
- prolgolimabBCD-100, FortecaPhase 31 trial
Biocad · Melanoma, Melanoma (Skin), Melanoma Stage III
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.